While each vaccine was able to induce specific IFN-γ responses against an MHC Class I epitope within their respective regions, only two of the vaccines, Lm-FlkE1 and Lm-FlkI1, were able to significantly inhibit Her2/neu+ breast tumor growth, reduce tumor vascularization, and induce secondary T cell responses against the non-targeted TAAs, a process known as epitope spreading (Vanderlugt and Miller, 2002). The gene discussed is ERBB2; the disease is neoplasm.